Literature DB >> 23489559

Tumor-associated macrophages in thoracic malignancies.

L A Lievense1, K Bezemer, J G J V Aerts, J P J J Hegmans.   

Abstract

Tumor-associated macrophages (TAMs) can be abundantly present in numerous cancer types. Under influence of various stimuli in the tumor microenvironment TAMs develop into a tumor-inhibitory (M1) or tumor-promoting (M2) phenotype. Recently, the role of TAMs in tumor biology and their prognostic value in cancer has become a major topic of interest. In this review we will discuss the importance of TAMs in the pathogenesis and clinical outcome of lung cancer and mesothelioma patients. In addition, the potential of TAMs as therapeutic targets will be discussed.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Year:  2013        PMID： 23489559     DOI： 10.1016/j.lungcan.2013.02.017

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


  24 in total

1.  Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.

Authors:  Elly Marcq; Vasiliki Siozopoulou; Jorrit De Waele; Jonas van Audenaerde; Karen Zwaenepoel; Eva Santermans; Niel Hens; Patrick Pauwels; Jan P van Meerbeeck; Evelien L J Smits
Journal:  Oncoimmunology       Date:  2016-11-28       Impact factor: 8.110

2.  Prognostic significance of the preoperative lymphocyte-to-monocyte ratio in patients with colorectal cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Yasuhito Iseki; Tetsuro Ikeya; Kosei Hirakawa
Journal:  Oncol Lett       Date:  2016-12-12       Impact factor: 2.967

3.  Monocytic myeloid-derived suppressor cells as a potent suppressor of tumor immunity in non-small cell lung cancer.

Authors:  Katarzyna Pogoda; Maria Pyszniak; Paweł Rybojad; Jacek Tabarkiewicz
Journal:  Oncol Lett       Date:  2016-10-18       Impact factor: 2.967

Review 4.  The role of STAT3 in tumor-mediated immune suppression.

Authors:  Sherise D Ferguson; Visish M Srinivasan; Amy B Heimberger
Journal:  J Neurooncol       Date:  2015-02-22       Impact factor: 4.130

Review 5.  Novel insights into mesothelioma biology and implications for therapy.

Authors:  Timothy A Yap; Joachim G Aerts; Sanjay Popat; Dean A Fennell
Journal:  Nat Rev Cancer       Date:  2017-07-25       Impact factor: 60.716

Review 6.  Immunotherapy prospects in the treatment of lung cancer and mesothelioma.

Authors:  Joachim G Aerts; Lysanne A Lievense; Henk C Hoogsteden; Joost P Hegmans
Journal:  Transl Lung Cancer Res       Date:  2014-02

7.  Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer.

Authors:  Se-Il Go; Rock Bum Kim; Haa-Na Song; Myoung Hee Kang; Un Seok Lee; Hye Jung Choi; Seung Jun Lee; Yu Ji Cho; Yi Yeong Jeong; Ho Cheol Kim; Jong Deog Lee; Seok-Hyun Kim; Jung-Hun Kang; Hui Ling; Gyeong-Won Lee
Journal:  Med Oncol       Date:  2014-11-23       Impact factor: 3.064

8.  Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma.

Authors:  Abdullah Cetin Tanrikulu; Abdurrahman Abakay; Halil Komek; Ozlem Abakay
Journal:  Environ Health Prev Med       Date:  2016-04-11       Impact factor: 3.674

9.  Small cell lung cancer: Recruitment of macrophages by circulating tumor cells.

Authors:  Gerhard Hamilton; Barbara Rath; Lukas Klameth; Maximilan J Hochmair
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

Review 10.  Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

Authors:  Stefan Kiesgen; Leonardo Chicaybam; Navin K Chintala; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2017-10-26       Impact factor: 15.609
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.